PLUS THERAPEUTICS INC (PSTV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.10+2.65%
Close 2026-08-27 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PSTV
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Progress REYOBIQ Phase 2 trials in leptomeningeal metastases and glioblastoma, initiate pediatric brain cancer trial, and engage FDA for pivotal trial planning.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2. Management emphasized advancing REYOBIQ clinical trials with approximately one-third enrollment in ReSPECT-LM by 2026-Q2 and expected data from ReSPECT-GBM in Q1 2027. FDA Orphan Drug Designation for pediatric gliomas was secured in 2026-Q1. The trajectory shows active progress and regulatory engagement consistent with stated goals.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Continued enrollment in ReSPECT-LM and ReSPECT-GBM Phase 2 trials; initial site activation of ReSPECT-PBC pediatric trial.”
“Progressing on ReSPECT-LM clinical trial; secured FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas.”
Grow CNSide assay commercial operations, increase U.S. payer coverage beyond 150 million lives, secure Medicare coverage, and scale test orders.
Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. CNSide payer coverage grew from approximately 81 million lives in 2026-Q1 to 150 million by mid-2026-Q2. Medicare enrollment and commercial team expansion support the rollout. The trajectory shows delivering on commercial scale-up and payer coverage expansion.
“Achieved 150 million covered lives for CNSide commercial payer coverage by mid-year 2026.”
“Expanded payer coverage to approximately 81 million lives; enrolled CNSide with Medicare.”
“Expect CNSide Diagnostics to breakeven by 2027 with expanded commercial operations team.”
Manage operating expenses with expanded CNSide commercial operations, secure capital through equity offerings, and maintain cash balance to support milestones.
Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Operating loss increased from $7.1M in 2026-Q1 to $9.1M in 2026-Q2 reflecting CNSide commercial expansion and REYOBIQ trial funding. The company raised $15M in Q1 2026 via public offering, supporting capital resources. Cash and investments declined but remain sufficient to support milestones. The trajectory shows managing financial resources with increased spending aligned to stated priorities.
“Operating loss increased due to CNSide commercial expansion and REYOBIQ Phase 2 trial funding.”
“Completed upsized public offering generating $15 million gross proceeds to support CNSide commercialization and clinical programs.”
“Expect G&A expenditures to increase in 2026 due to expanded CNSide commercial operations; goal for CNSide Diagnostics breakeven by 2027.”
Develop and integrate CNSide diagnostics, REYOBIQ therapeutics, and AI-driven data analytics to improve CNS cancer patient outcomes.
Newly stated in 2026-Q2. Management described building an integrated CNS oncology platform combining diagnostics, therapeutics, and AI. No specific financial or operational metrics were provided yet to measure delivery. The statement reflects strategic intent with limited substantive delivery so far.
“Advancing integrated CNS oncology platform combining precision diagnostics, targeted therapeutics, and AI.”
Appoint senior executives to support clinical development, market access, and R&D execution for CNS oncology programs.
Newly stated in 2026-Q1. Management announced key senior appointments including Chief Development Officer to strengthen clinical development and market access capabilities. No financial or operational metrics were provided to assess delivery. This reflects a strategic talent priority with initial execution.
“Appointed Eric J. Daniels, M.D., MBA, as Chief Development Officer and other senior leadership hires.”
Over the trailing year it converted 0.60x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates, the US dollar (low R² over the window).
20 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 53% of the time over the next year (vs 50% for the rest of the cohort, n=3986).
Not investment advice. As of 2026-09-04.